IP Library Granted Patent US 10,124,014
Granted Patent B2
US 10,124,014 · App. 15/637,144 · Granted Nov 13, 2018

Minocycline compounds and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,124,014
App. No.
15/637,144
Granted
Nov 13, 2018
Kind
B2
Abstract

Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B - streptococci, Viridans Streptococci, Enterococcus , or combinations thereof.

Claims (2)

1. A method of treating a human subject for complicated Skin and Skin Structure Infections, comprising intravenously administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein gastrointestinal (GI) adverse events (AEs) associated with treatment are mild, and wherein said subject is treated up to and including about 14 days, up to and including about 10 days, up to and including about 9 days, up to and including about 8 days, or up to and including about 7 days, such that said subject is treated.

2. A method of treating a human subject for complicated Skin and Skin Structure Infections, comprising intravenously administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein gastrointestinal (GI) adverse events (AEs) associated with treatment are mild, wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered intravenously, followed by an oral administration, and wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered intravenously for about 2-6 days, and total treatment period including intravenous and oral administration is about 8-12 days.

Assignments (6)
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 71200/0656 Recorded Mar 17, 2026
From: OAKTREE FUND ADMINISTRATION, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 075101/0815 →
PATENT SECURITY AGREEMENT Recorded Mar 16, 2026
From: PARATEK PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 075111/0244 →
SECURITY INTEREST Recorded May 22, 2025
From: PARATEK PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 071200/0656 →
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 065001/0917 Recorded May 22, 2025
From: OAKTREE FUND ADMINISTRATION, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 071343/0407 →
SECURITY INTEREST Recorded Sep 22, 2023
From: PARATEK PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 065001/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2017
From: ARBEIT, ROBERT D.; BIGGER, THOMAS J.; JOHNSTON, SEAN M.; MOLNAR, DENNIS P.; TANAKA, S. KEN
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 043166/0981 →